Q2 2026 MDB Capital Holdings LLC Earnings Call Transcript
Key Points
- MDB Capital Holdings LLC (MDBH) is focusing on monetizing its four core assets (Public Ventures, PatentVest, eXoZymes, and Paulex Bio) to reach key value inflection points, with a clear plan to avoid dilution for shareholders.
- The company is actively pursuing partnerships or a sale of its Public Ventures clearing platform, with interest from multiple parties and a potential deal expected within the next quarter, which could unlock significant value.
- PatentVest has pivoted to an AI-enabled ABS law firm model, positioning it as a leader in the future of patent law, with a financing round planned to spin it out as an independent entity, attracting external investors.
- eXoZymes is nearing commercial inflection points, including potential strategic manufacturing partnerships and commercial deals, which could drive substantial valuation expansion similar to past successes.
- Paulex Bio is close to filing for an IPO, with promising preclinical data on beta cell expansion for diabetes, potentially leading to a major value-creating event for MDBH.
- MDBH is committed to operating with financial discipline, targeting $5-6 million in annual operational expenses, which can be offset by fees, ensuring sustainability without dilution.
- The company has a strong track record of 17 IPOs over 29 years, with all trading at significant premiums post-IPO, and management remains confident in the potential for future value creation.
- MDBH is leveraging its close to three decades of experience to actively help portfolio companies like eXoZymes and Paulex Bio with commercialization and investor outreach, enhancing their value.
- The company is exploring nondilutive funding options for eXoZymes, such as spin-outs or strategic investments, to reduce capital needs and create value.
- Management is actively engaging with investors through podcasts and conferences to communicate the company's story and the leverage embedded in its shares.
- MDB Capital Holdings LLC (MDBH) is operating in a challenging microcap market, with the sub-$200 million market cap sector being largely neglected by investors, leading to depressed stock prices.
- The company's stock price is down from its IPO, and management acknowledges dissatisfaction with this performance, which may erode investor confidence.
- The plan to scale new company launches from one every 18 months to three to five per year has been put on hold due to unfavorable market conditions, limiting growth opportunities.
- The company's financial results are described as 'lumpy' due to the irregular nature of transactions, which can make it difficult for investors to predict performance.
- eXoZymes' recent financing raised only $6 million, below expectations, highlighting challenges in raising capital in the current environment.
- The microcap market's lack of institutional participation and fund flows is a significant headwind, as many small companies struggle to gain coverage and valuation expansion.
- There is a risk that the anticipated value inflection points for portfolio companies may not materialize as expected, given the volatile nature of the sector.
- The company's efforts to attract new investors are hampered by the asset class being out of favor, with conferences and podcasts having limited reach.
- PatentVest's pivot to an AI-enabled law firm is a significant strategic shift that carries execution risks, and the success of the spin-out is uncertain.
- The potential partnership or sale of Public Ventures is not guaranteed, and if it fails, the platform may remain underutilized, adding to operational costs.
Welcome, everyone, to the MDB Capital Holdings second quarter and first half 2026 update conference Call. Thanks so much for joining us today.
(Event Instructions) Please remember that statements made on this call and webcast may contain provisions, estimates or other information that might be considered forward-looking.
While these forward-looking statements represent our current judgment on what the future holds, they're subject to risks and uncertainties that could cause actual results to differ materially.
You're cautioned not to place undue reliance on these forward-looking statements, which reflect our opinions only as of the date of this presentation.
Also, please be aware that we are not obligating ourselves to revise or publicly release results or any revision to these forward-looking statements in light of new information or future events.
Throughout today's discussion, we'll attempt to present some important factors relating to our business that may affect our predictions. You
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
